Free/total PSA ratio improves differentiation of benign and malignant disease of the prostate: Critical analysis of two different test populations

Urology

Volumn 53, Issue 4, 1999, Pages 736-745

  Veltri, Robert W ^a   Craig Miller, M ^a  

^a UroCor Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RISK; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; HALF LIFE TIME; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY;

AGED; DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY;

EID: 0033119703     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00617-7     Document Type: Article

References (30)

1. 1-antichymotrypsin. Clin Chem 37: 1618-1625, 1991.
2. McCormack RT, Rittenhouse HG, Finlay JA, et al: Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45: 729-744, 1995.
3. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 51: 222-226, 1991.
4. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 150: 100-105, 1993.
5. Partin AW, and Oesterling JE: The clinical usefulness of prostate specific antigen: update 1994. J Urol 152: 1358-1368, 1994.
6. Oesterling JE: Molecular PSA: the next frontier in PSA screening. Contemp Urol 8: 76-92, 1996.
7. Partin AW, and Oesterling JE (Eds): The Clinical Use-fulness of Percent Free Prostate-Specific Antigen. Urology 48(Suppl 6A): 1-87, 1996.
8. Richardson TD, Wojno KJ, Liang LW, et al: Half-life determination of serum free prostate-specific antigen following radical prostatectomy. Urology 48(suppl 6A): 40-44, 1996.
9. Woodrum D, French C, and Shamel B: Stability of free-prostate specific antigen in serum samples under a variety of sample collection and sample storage conditions. Urology 48(suppl 6A): 33-39, 1996.
10. Orstein DK, Smith DS, Rao GS, et al: Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 157: 2179-2182, 1997.
11. 1-antichymotrypsin: potential reference material for international standardization of PSA immunoassays. Clin Chem 41: 1273-1282, 1995.
12. Stamey TA: Second Stanford conference on international standardization of prostate-specific antigen immunoassays: Sept. 1&2, 1994. Urology 45: 173-184, 1995.
13. Catalona WJ, Smith DS, Wolfert RL, et al: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
14. Oesterling JE, Jacobsen SJ, Klee GG, et al: Free, complex ed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol 154: 1090-1095, 1995.
15. Marley GM, Miller MC, Kattan MW, et al: Free and complexed prostate specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasia. Urology 48(suppl 6A): 16-22, 1996.
16. Prestigiacomo AF, Lilja H, Pettersson K, et al: A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. J Urol 156: 350-354, 1996.
17. Carter HB, Partin AW, Luderer AA, et al: Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. Urology 49: 379-384, 1997.
18. Bangma CH, Rietbergen JEW, Kranse R, et al: The free-to-total prostate-specific antigen ratio improves the specificity of prostate-specific antigen in screening for prostate cancer in the general population. J Urol 157: 2191-2196, 1997.
19. Chen YT, Luderer AA, Thiel RP, et al: Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. Urology 47: 518-524, 1996.
20. Partin AW, Catalona WJ, Southwick PC, et al: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume and age. Urology 48(suppl 6A): 55-61, 1996.
21. Morgan TO, McCloed DG, Leifer ES, et al: Prospective use of free PSA to avoid repeat biopsies in men with elevated total PSA. Prostate 7: 58-63, 1996.
22. Thiel RP, Oesterling JE, Wojno KJ, et al: Multicenter comparison of the diagnostic performance of free prostate-specific antigen. Urology 48(suppl 6A): 45-50, 1996.
23. Allard WJ, Zhou Z, and Yeung KK: Novel measurement of complex prostate-specific antigen in serum. Clin Chem 44: 1216-1223, 1998.
24. Hosmer DW, and Lemeshow S: Applied Logistic Regression. New York, John Wiley & Sons, 1989.
25. Vollmer RT: Multivariate statistical analysis for pathologists. Am J Clin Pathol 105: 115-126, 1996.
26. Whittemore AS: Logistic regression of family data from case-control studies. Biometrika 82: 57-67, 1995.
27. Morise AP, Diamond GA, Detrano R, et al: The effect of disease-prevalence adjustments on the accuracy of a logistic prediction model. Med Dec Making 16: 133-142, 1996.
28. Nixon RG, Meyer GE, Blasé AB, et al: Comparison of 3 investigational assays for the free form of prostate specific antigen. J Urol 160: 420-425, 1998.
29. Veltri RW, Miller MC, Zhao G, et al: lnterleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology 53: 139-147, 1999.
30. Saedi MS, Hill TM, Kuus-Reichel K, et al: The precursor form of the human kallikrein 2, a kallikrein homologous to prostate-specific antigen, is present in human sera and is increased in prostate cancer and benign prostatic hyperplasia. Clin Chem 44: 2115-2119, 1998.